| P50 | author | Brian R. Murphy | Q65658906 |
| P2093 | author name string | Jerrold M Ward | |
| | Alexander Bukreyev | |
| | Lijuan Yang | |
| | Peter L Collins | |
| | Anthony Sanchez | |
| P2860 | cites work | Ebola haemorrhagic fever in Zaire, 1976 | Q24650229 |
| | Respiratory syncytial virus infects and abortively replicates in the lungs in spite of preexisting immunity | Q24676109 |
| | Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates | Q27469676 |
| | Development of a preventive vaccine for Ebola virus infection in primates | Q28140401 |
| | Overcoming immunity to a viral vaccine by DNA priming before vector boosting | Q28217213 |
| | Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection | Q30310545 |
| | Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. | Q33783083 |
| | Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. | Q33840716 |
| | Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity | Q33908767 |
| | Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses | Q33987611 |
| | Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus | Q34057893 |
| | Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats | Q34080111 |
| | Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates | Q34092801 |
| | Other viral bioweapons: Ebola and Marburg hemorrhagic fever | Q34327893 |
| | Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory | Q34370420 |
| | Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. | Q34389544 |
| | A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge | Q34434713 |
| | Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge | Q34583832 |
| | Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics | Q34717853 |
| | Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. | Q34791255 |
| | Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene | Q34996554 |
| | Nonsegmented negative-strand viruses as vaccine vectors | Q35139219 |
| | Successful topical respiratory tract immunization of primates against Ebola virus | Q35857218 |
| | Exotic emerging viral diseases: progress and challenges | Q35971398 |
| | Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium | Q37743793 |
| | Multiple Ebola virus haemorrhagic fever outbreaks in Gabon, from October 2001 to April 2002 | Q40494823 |
| | Molecular characterization of guinea pig-adapted variants of Ebola virus | Q40612653 |
| | Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors | Q40624940 |
| | A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. | Q40675926 |
| | Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins | Q40722324 |
| | Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans | Q43000500 |
| | Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus | Q43708485 |
| | Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections | Q44089771 |
| | Monoclonal antibodies to the E1 and E2 glycoproteins of Sindbis virus: definition of epitopes and efficiency of protection from fatal encephalitis | Q44302411 |
| | Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections | Q45416549 |
| | Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity | Q45736005 |
| | Recovery of infectious human parainfluenza virus type 3 from cDNA. | Q45760781 |
| | Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus | Q45858547 |
| | Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity | Q47644096 |
| | Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity | Q70998772 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Orthoebolavirus zairense | Q10538943 |
| | vector-borne disease | Q2083837 |
| | Ebola vaccine | Q3553092 |
| P304 | page(s) | 255-264 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Virology | Q7934867 |
| P1476 | title | A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals | |
| P478 | volume | 377 | |